Peptide-based therapeutics have transformed obesity and diabetes treatment, with multi-receptor agonists representing the most promising next-generation approaches.
Up to 24% weight lossRange of weight reduction achieved by the latest peptide-based obesity medications
What the researchers found
Peptide-based metabolic regulators — particularly multi-receptor agonists targeting GLP-1, GIP, and glucagon receptors — have emerged as the most effective pharmacological class for obesity and T2DM treatment.
Why it matters
Understanding the full landscape of peptide drugs helps clinicians choose the best current options and anticipate even more effective treatments in the pipeline.
How the study worked
Comprehensive narrative review of clinical trials involving peptide therapeutics for obesity and type 2 diabetes, covering historical development through current and pipeline agents.
What this study cannot tell us
Narrative review — not a systematic analysis. May not capture all ongoing trials. Focus on clinical efficacy may underweight safety and cost considerations.
How to read the evidence
Narrative review synthesizing clinical trial data — provides a comprehensive overview but not a quantitative meta-analysis.
When this study was published
Published in 2026; covers the latest approved and pipeline peptide drugs.
The bigger picture
The peptide therapeutics revolution in metabolic disease is accelerating, with each generation of drugs achieving greater efficacy and the gap between pharmacotherapy and surgery continuing to narrow.
Questions still open
- Will triple agonists like retatrutide surpass tirzepatide in weight loss efficacy?
- Can oral peptide formulations achieve comparable efficacy to injectable versions?
Common questions
What peptide drugs are available for weight loss?
How do peptide drugs work for obesity?
Read the original research
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials.
Clinica chimica acta; international journal of clinical chemistry, 581, 120772
Citation
Barzgar, Haniyeh; Darmadi, Darmadi; Nafisa, Jabbarova; Narkulov, Suxrob; Sviridova, Maria B. (2026). Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials.. Clinica chimica acta; international journal of clinical chemistry, 581, 120772. https://doi.org/10.1016/j.cca.2025.120772